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Clinical trials have demonstrated morbidity and mortality benefits of mineralocorticoid receptor antagonists (MRAs) in patients with heart
failure. These studies have used either spironolactone or eplerenone as the MRA. It is generally believed that these two agents have the
same effects, and the data from studies using one drug could be extrapolated for the other. National and international guidelines do not
generally discriminate between spironolactone and eplerenone, but strongly recommend using an MRA for patients with heart failure due
to LV systolic dysfunction and post-infarct LV systolic dysfunction. There are no major clinical trials directly comparing the efficacy of these
two drugs. This article aims to compare the pharmacokinetics and pharmacodynamics of spironolactone and eplerenone, and to analyse the
available data for their cardiovascular indications and adverse effects. We have also addressed the role of special circumstances including
co-morbidities, concomitant drug therapy, cost, and licensing restrictions in choosing an appropriate MRA for a particular patient, thus
combining an evidence-based approach with personalized medicine.
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Introduction
Mineralocorticoid receptor antagonists (MRAs) improve outcomes
in patients with chronic heart failure (CHF) caused by LV sys-
tolic dysfunction (LVSD).1–3 Eplerenone and spironolactone (or
its metabolite, potassium canrenoate) are the currently licensed
MRAs for clinical use. Clinical studies show the benefit of MRAs,
but there are limited data on direct comparison of these MRAs.
It is generally believed that the benefits of different MRAs repre-
sent a ‘class effect’. National and international guidelines including
those from the American Heart Association (AHA) and European
Society of Cardiology (ESC) do not discriminate between spirono-
lactone and eplerenone, but strongly recommend using these for
patients with CHF and post-infarct LVSD.4,5
Spironolactone and eplerenone differ in their molecular
structure, pharmacokinetics, and pharmacodynamics (Table 1).
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.. Spironolactone is a non-specific MRA and, due to its structural sim-
ilarity to progesterone,6 has affinity for progesterone, androgen,
and glucocorticoid receptors. Eplerenone is chemically different,7
and substitution of the 17-𝛼-thioacetyl group of spironolactone
with a carbomethoxy group in eplerenone provides greater selec-
tivity for mineralocorticoid receptors (MRs) and minimal binding
to progesterone and androgen receptors.6 Spironolactone has
substantially greater affinity for MRs than eplerenone, which is
important to consider when comparing similar doses of these two
drugs. Spironolactone and eplerenone differ in their metabolism
and half-life.6,8 Eplerenone produces more consistent inhibition
of the rapid non-genomic effects of aldosterone (including coro-
nary vasoconstriction, increased systemic vascular resistance,
and potentiation of the vasoconstrictor effect of angiotensin
II in coronary arteries) than spironolactone.7,9 Based on these
biochemical and pharmacological differences, this review aims to
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Table 1 Comparison of biochemical and pharmacological properties of spiranolactone and eplerenone
Spironolactone Eplerenone
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chemical structure
Chemical formula C24H32O4S C24H30O6
Mode of action Competitive MR antagonism Competitive MR antagonism
MR affinity High 10- to 20-fold lower
MR selectivity Non-selective (also binds to glucocorticoid,
progesterone, and androgen receptors)
Higher selectivity for MR
Inhibition of non-genomic MR effects No Yes
Onset/offset of action Slow Quicker
Bioavailability 60–90% Absolute bioavailability unknown
Volume of distribution Unknown 43–90 L
Protein binding 90% bound to plasma proteins 50% bound to plasma proteins
Metabolism Hepatic metabolism to active metabolites Hepatic metabolism by CYP3A4 to inactive
metabolites
Half-life of drug 1–2 h 4–6 h
Active metabolites Yes No
Elimination half-life of drug and metabolites 10–35 h 4–6 h
MR, mineralocorticoid receptor.
compare systematically the available data to evaluate whether
spironolactone and eplerenone can be substituted for each other
for their cardiovascular indications.
Mineralocorticoid receptor
antagonists for systemic
hypertension
Mineralocorticoid receptor antagonists are effective in reducing
blood pressure (BP) when used as monotherapy10,11 or in com-
bination regimens.11–13 MRAs have been shown to be as effec-
tive as ACE inhibitors or ARBs in lowering BP.14 Furthermore, it
has also been suggested that MRAs can reduce BP as effectively
as calcium channel blockers and, additionally, may have a more
potent effect on reducing microalbuminuria.15 Eplerenone has been
shown to be better tolerated than the widely used calcium chan-
nel blocker amlodipine, with comparable reductions in systolic
BP.16 MRAs have also been shown to prevent end-organ damage
in both pre-clinical17 and clinical studies.18,19 Furthermore, in the
EPHESUS trial, eplerenone-associated reduction in all-cause mor-
tality was significantly greater in those with a history of systemic
hypertension.2 The use of MRAs as anti-hypertensive agents, how-
ever, remains low. Current guidelines consider MRAs as fourth-line
therapy for essential hypertension (except for patients with hyper-
tension secondary to hyperalodsteronism, where it is first line),20
which effectively limits their use to resistant hypertension only.
Further large-scale studies showing efficacy, safety, and end-organ ..
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. protection are warranted before MRAs can be moved higher up in
the treatment algorithm for essential hypertension.21
The two MRAs have been directly compared in a few trials
of systemic hypertension. A multicentre, double-blind, placebo-
controlled trial in >400 patients with mild to moderate essential
hypertension evaluated the efficacy, safety, and tolerability of the
two MRAs over an 8-week treatment period and found that the
magnitude of reduction in BP with eplerenone (100mg daily)
was 25% less than that with a similar dose of spironolactone,
suggesting that spironolactone may have a more potent effect on
BP.22 The antihypertensive effect of spironolactone has also been
shown to be greater than that of eplerenone in systemic hyper-
tension associated with primary aldosteronism; a multicentre,
double-blind, parallel-group, randomized, controlled trial showed
that spironolactone (75–225mg once daily) had almost a two-fold
greater BP-lowering effect than eplerenone (100–300mg once
daily).23 Another randomized, open-label, blinded-endpoint study
compared spironolactone (25mg twice a day) and eplerenone
(25mg twice a day) in patients with idiopathic hyperaldosteronism,
and found that an equal proportion of patients achieved normal
BP in both groups.24 However, the BP-lowering effect of spirono-
lactone was greater than that of equal doses of eplerenone.24 The
more potent and prolonged effect of spironolactone in lowering
BP may be due to the longer half-life of its active metabolites, as
compared with eplerenone.6,8
These data suggest that spironolactone is more effective than
eplerenone when used at the same doses and, although there is no
dose equivalence between the two drugs, spironolactone could be
© 2013 The Authors
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used as first-choice MRA in the treatment of essential or secondary
hypertension. However, if patients develop spironolactone-related
adverse effects, then it may be worth switching to eplerenone,
probably at a higher dose.
Mineralocorticoid receptor
antagonists for heart failure
National and international guidelines recommend MRAs for
patients with CHF caused by LVSD,4,5 based on morbidity and
mortality benefits seen in three landmark trials (RALES, EPHESUS,
and EMPHASIS-HF).1–3 These trials are not, however, directly
comparable due to considerable differences in patient populations
and trial design.25 The RALES trial consisted of patients with
advanced CHF, the EPHESUS trial included patients with LVSD
after acute myocardial infarction (AMI), and the EMPHASIS-HF
trial enrolled CHF patients with mild (NYHA II) symptoms.1–3
Baseline drug therapy, especially the use of beta-blockers and
ACE inhibitors, also differed markedly among these trials and
could partially account for the observed differences in mortality
reduction in these trials. Based on these differences, caution is
warranted in directly comparing the results of these trials. Chat-
terjee et al. have recently carried out an ‘indirect pooled analysis’
of 13 studies using spironolactone (or canrenone) and eplerenone,
and suggested that eplerenone was outperformed by other MRAs
(15% vs. 26% reduction in all-cause mortality and 17% vs. 25%
reduction in cardiac mortality).26 However, this comparison is
misleading for a variety of reasons. This analysis included some
small trials with <100 subjects or short follow-up of 2–3months
duration, which may not be relevant to measure mortality or
safety endpoints. Without these limitations, only three studies
(EPHESUS, EMPHASIS-HF, and RALES) drove the results. However,
these three trials cannot be directly compared due to differences
in trial population and design (Table 2). We believe that available
data have to be analysed at patient and trial level to decide on
evidence-based use of the two MRAs. We will compare the use of
these drugs for different forms of heart failure separately.
Table 2 Differences in RALES, EPHESUS, and
EMPHASIS-HF trials
RALES EPHESUS EMPHASIS-HF
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Patient number 1663 6632 2737
Drug Spironolactone Eplerenone Eplerenone
Mean drug dose (mg) 26 44 39
NYHA class III–IV I–IV II
LVEF (%) 26 33 26
Ischaemic aetiology (%) 55 100 70
ACE inhibitor/ARB (%) 95 86 94
Beta-blockers (%) 11 75 87
Diuretics (%) 100 60 84
Years of recruitment 1995–96 1999–2001 2006–10
Mean follow-up
(months)
24 16 21
Mortality in placebo
group at 1 year (%)
27 14 7
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.. Chronic heart failure due to left
ventricular systolic dysfunction
RALES and EMPHASIS-HF have evaluated the efficacy of the
two MRAs in CHF due to LVSD, showing that both drugs were
effective in reducing mortality. In RALES, spironolactone produced
a 30% relative reduction in mortality during an average follow-up
of 24months.1 In EMPHASIS-HF, there was a 24% reduction in
cardiovascular death and a 42% reduction in hospitalization for
heart failure.3 Based on individual trial design, it could be suggested
to use spironolactone for advanced CHF and eplerenone for CHF
with mild symptoms. However, it is counterintuitive to believe
that these drugs will be effective in patients with only severe or
mild symptoms, respectively. It may be tempting to think that
either of these two drugs could be used in CHF due to LVSD. One
possible limitation to this ‘class effect’ reasoning is the concern
about dosing. In the ‘real world’, spironolactone is being used
overwhelmingly, even in mild to moderate CHF, at doses used in
the RALES trials. Several observational studies, inherently of less
value than prospective randomized trials, have raised concerns
that MRAs (mainly spironolactone) may not be as effective and
safe as suggested by the results of the three main randomized
trials.27 This could possibly be due to off-label usage in higher risk
groups, inappropriate dosing, or lack of careful monitoring, factors
which are seldom seen in the settings of a clinical trial. Based on
good evidence-based practice, one can expect the benefit–risk
ratio shown in individual trials only when using the same drugs and
dosages as used in corresponding trials. Therefore, until further
data are available, it might be prudent to use the MRA and dosing
regimens proven to be safe and effective in the major randomized
trials, i.e. spironolactone 12.5–50mg/day in patients with severe
CHF due to LVSD and eplerenone 25–50mg/day in patients with
CHF due to LVSD and mild symptoms. Indeed, this approach has
been adopted in some of the guidelines.28,29
Left ventricular systolic dysfuntion after
myocardial infarction
Both spironolactone and eplerenone have been shown to improve
LV pressure recovery following ischaemia and reperfusion in pre-
clinical studies.30 Spironolactone has not been studied in clinical
trials for this indication. In the landmark EPHESUS trial, a mean
dose of 43mg of eplerenone produced 15% reduction in all-cause
mortality, 17% reduction in cardiovascular mortality, and 21%
reduction in sudden cardiac death (SCD).2
Although lack of clinical data does not mean that spironolactone
has no effect in post-infarct LVSD, the evidence-based approach
suggests that eplerenone, and not spironolactone, should be rec-
ommended for post-infarct LVSD patients, as suggested by the
National Institute for Health and Clinical Excellence (NICE), UK.
Furthermore, patients with MI are frequently treated with PCIs,
and eplerenone (but not spironolactone) may also prevent in-stent
restenosis.31 Spironolactone was shown to inhibit post-angioplasty
restenosis in rabbits.32 However, these results could not be repro-
duced in a porcine coronary angioplasty model31 or in a clinical
trial.33 However, eplerenone has shown promising results in many
pre-clinical models.31,34,35 This differential effect of eplerenone
© 2013 The Authors
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could possibly be due to substantial (65%) reduction in collagen
content in the neointima and media, which spironolactone has not
been shown to reduce.31 Furthermore, whilst eplerenone is selec-
tive for MRs, spironolactone may also block progesterone recep-
tors (progesterone has been shown to have antiatherosclerotic and
antirestenotic properties by inhibiting foam cell formation).36 The
efficacy of eplerenone for this indication has not been formally
tested in a clinical trial. However, in the EPHESUS trial, 24% of
patients received PCI as a treatment for AMI and, although there
was no statistically significant interaction, the magnitude of benefi-
cial effects of eplerenone, as compared with placebo, was greater
in PCI-treated patients compared with patients who did not have
PCI.2 There are currently two ongoing trials to test MRAs in an
AMI population: ALBATROSS (NCT-01059136) and REMINDER
(NCT-01176968) testing spironolactone and eplerenone, respec-
tively. Both agents will be administered within 24 h of an AMI.
These trials may help understand potential similarities and differ-
ences between the two MRAs.
Prevention of sudden cardiac death
in heart failure
Mineralocorticoid receptor antagonists, in addition to standard
therapy, reduced the incidence of SCD in the RALES, EPH-
ESUS, and EMPHASIS-HF trials.1–3 Spironolactone has been shown
to improve electrophysiological parameters such as QT interval
dispersion.37 Furthermore, spironolactone, in combination with
ACE inhibitors, reduced arrhythmias in post-MI patients.38 MRAs
acutely improve cardiac vagal control, irrespective of any diuretic
effects, which may partially explain their beneficial effects.39 Wei
et al. performed a meta-analysis of MRA trials to evaluate their
role in the prevention of SCD in heart failure patients.40 This
meta-analysis included seven trials with a total of 8635 patients. All
eplerenone data were derived from the EPHESUS trial. The major-
ity of the spironolactone data came from the RALES trial, whilst
the other five trials (all with spironolactone) contributed only 340
patients in this meta-analysis. Both MRAs significantly reduced the
risk of SCD, ventricular tachycardia, and episodes of ventricular
premature complexes (Table 3).40
In summary, both drugs have a potential, and similar, role in
prevention of ventricular arrhythmias and SCD in CHF patients.
Hence, this indication does not affect the choice of which MRA
should be used. Thus, the choice continues to be based on the
severity of symptoms and the circumstances of heart failure (post-
infarct or not).
Heart failure with preserved ejection
fraction
Heart failure with preserved ejection fraction (HF-PEF) or diastolic
heart failure (DHF) is pathophysiologically different from heart
failure due to LVSD.41 Hence, the data from studies evaluating the
effects on patients with heart failure due to LVSD should not be
directly extrapolated to diastolic dysfunction.
Mineralocorticoid receptor activation leads to LV hypertrophy
and collagen deposition, which reduces compliance.42 Eplerenone ..
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Table 3 Mineralocorticoid receptor antagonists for
prevention of sudden cardiac death
Spironolactone Eplerenone
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Dose (mg/day) 25 25–50
Patient number 1663 6632
NYHA class III or IV II
LVEF <35% <40%
Follow-up 24 16
VA
hospitalization
Spironolactone 2.8%
vs. control 2.8%,
P= 0.9
Eplerenone 1.6%
vs. control 1.6%,
P= 0.8
Sudden cardiac
death
Spironolactone 10%
vs. control 13%,
P= 0.02
Eplerenone 4.9%
vs. control 6.1%,
P= 0.03
VA, ventricular arrhythmias.
has been shown to attenuate collagen turnover in patients with
DHF43,44 and to improve the echocardiographic measures of dias-
tolic function.44 There was, however, no significant improvement in
6min walk distance.44 Furthermore, any benefit of eplerenone on
morbidity and mortality in HF-PEF remains to be demonstrated.
A few studies have assessed the effect of spironolactone on
diastolic dysfunction. Spironolactone (25mg/day) in combination
with ACE inhibitors improved myocardial function, reduced LV
hypertrophy, and reduced markers of collagen turnover in patients
with metabolic syndrome and already receiving ACE inhibitors.45
Aldo-DHF randomized 422 patients with DHF (NYHA II/III, EF
≥50% and echocardiographic evidence of diastolic dysfunction) to
receive either spironolactone (25mg/day) or placebo for a period
of 12months and revealed no improvement in exercise capac-
ity or quality of life, despite improved biochemical and echocar-
diographic features in the spironolactone group.46 TOPCAT is a
large (n= 3445) multicentre, randomized, double-blind, placebo-
controlled trial of spironolactone in patients with DHF.47 The trial
results were presented at AHA Scientific Sessions, November 18,
2013. During an average follow-up of 3.3 years, there was no differ-
ence in the primary endpoints (the rate of cardiovascular mortality,
aborted cardiac arrest, or heart failure hospitalization) between
the spironolactone and placebo groups (18.6% vs. 20.4%; HR 0.89,
95% CI 0.77–1.04). The rate of heart failure hospitalization was,
however, significantly reduced in the spironolactone group (12%
vs. 14.2%, HR 0.83, 95% CI 0.69–0.99).
In summary, for HF-PEF there is no current indication for
either agent. However, spironolactone can potentially be used for
reduction in heart failure hospitalisation in this challenging group
of patients with limited therapeutic options.
Right heart failure and pulmonary
arterial hypertension
Plasma aldosterone levels have been shown to correlate with pro-
gression of pulmonary arterial hypertension (PAH).48 Conversely,
MR blockade reduces the proliferation of pulmonary arterial
smooth muscle cells.49 Both spironolactone and eplerenone have
© 2013 The Authors
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been shown to prevent or reverse pulmonary vascular remodelling
and improve cardiopulmonary haemodynamics in murine models
of PAH.50
To date, no studies have evaluated the role of MRAs in patients
with PAH and right heart failure. The use of MRAs in the treatment
of PAH and right heart failure is, therefore, not licensed at the
moment (except as part of diuretic therapy), due to lack of clinical
evidence. However, the pre-clinical data appear promising and
clinical trials are warranted.
Other potential factors
in choosing a mineralocorticoid
receptor antagonist
Gender
Spironolactone can produce endocrine sexual side effects. It
can interfere with 17-hydroxylase activity (causing a decrease in
testosterone synthesis) and peripheral metabolism of testosterone
(causing changes in the testosterone to oestradiol ratio), resulting
in gynaecomastia,51 which is reported in 10–20% of the men
taking spironolactone.1,13 Hypertensive trials have directly com-
pared spironolactone and eplerenone, and suggest that eplerenone
causes fewer endocrine side effects, including gynaecomastia.22–24
As a significant proportion of men are likely to be affected with this
side effect, it is reasonable to offer eplerenone as an alternative
long-term therapy in male patients affected by gynaecomastia on
spironolactone or who elect not to be given spironolactone for
fear of developing that complication. In female patients, spirono-
lactone is likely to be better tolerated than in male patients and
should remain as first-line therapy. However, it must be kept
in mind that women receiving spironolactone can also develop
mastodynia and menstrual irregularities,22,23 and may require
switching to eplerenone, a manoeuvre that usually ameliorates
these symptoms.24
Heart failure with diabetes mellitus
Spironolactone and eplerenone are equally effective in CHF
patients with or without diabetes.52 However, spironolactone
has been shown to impair endothelial function, as measured by
acetylcholine-mediated vasodilatation, in patients with type 2 dia-
betes, possibly due to the worsening of glycaemic control and an
increase in plasma angiotensin II.53 In contrast, eplerenone could
improve coronary circulatory function (adenosine-stimulated
myocardial perfusion reserve) and endothelial function in dia-
betic patients already receiving ACE inhibitors.54 Furthermore,
spironolactone can increase HbA1c (glycated haemoglobin) levels
in patients with type 2 diabetes with or without nephropathy or
poorly controlled hypertension.53,55 In a study of 107 patients
with mild CHF, spironolactone increased HbA1c and cortisol levels
and reduced adiponectin levels over 4months, findings which
might be expected to herald an increased risk of developing
diabetes.56 However, eplerenone has no such effects, suggesting
the possibility of a differential effect, depending on the selectivity
of MR blockade.56 Therefore, it could be argued that eplerenone ..
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Table 4 Comparison of adverse events in
spironolactone and eplerenone chronic heart failure
with left ventricular systolic dysfunction trials
Spironolactone Eplerenone
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Main trial RALES EMPHASIS-HF
Mean drug dose
(mg)
26 39
Gynaecomastia (%) 9 0.5
Breast pain (%) 2 0.5
Adverse event (%) 82 72
Serious
hyperkalaemia
(K+ >6mmol)
1.2% in placebo and
1.7% in
spironolactone
group (P< 0.001)
1.9% in placebo and
2.5% in eplerenone
group (P= 0.3)
Discontinuation due
to adverse event
3% higher than
placebo group
2.4% less than
placebo group
is the preferred MRA for diabetics. However, it must be noted that
there are opposing reports on the relationship of HbA1c levels
and outcomes in patients with CHF.57,58 Therefore, caution is
warranted in interpreting the differences between eplerenone and
spironolactone in patients with diabetes in the absence of direct
comparative outcome trials.
Hyperkalaemia
Both drugs can cause hyperkalaemia, and the incidence of seri-
ous hyperkalaemia is likely to be higher in real life than in clinical
trials.1,2,59 There are no direct comparative data to differentiate
between the two agents in terms of risk of hyperkalaemia. How-
ever, the available evidence suggests that the risk of hyperkalaemia
may be lower with eplerenone (Table 4). In view of the greater affin-
ity of spironolactone for MRs, as well as its longer half-life, the risk
of hyperkalaemia may be greater with 25mg of spironolactone than
with 25mg of eplerenone, the starting doses of these drugs in the
landmark trials. Furthermore, if hyperkalaemia develops with MRA
treatment, it is likely to take a longer time to obtain normokalaemia
with spironolactone in view of its longer half-life.
Other co-morbidities
Spironolactone is also used for non-cardiac indications including
hyperaldosteronism, cirrhosis with ascites and portal hypertension,
and nephrotic syndrome. There have been no major placebo-
controlled, randomized trials comparing the relative efficacy of the
two drugs in the management of these conditions and, until more
data become available, it is reasonable to start with spironolactone
in these co-morbid conditions and switch to eplerenone if side
effects are limiting.
Concomitant therapy
Caution is warranted for patients on multiple drugs to avoid
potential drug interaction and altered metabolism of drugs.25
Eplerenone is metabolized primarily by cytochrome P450 3A4
(CYP3A4); therefore, it should be avoided in patients receiving
© 2013 The Authors
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potent inhibitors of this enzyme, such as ketoconazole (may induce
a five-fold increase in eplerenone levels). Closer monitoring may
be needed when eplerenone is used with less potent inhibitors
of CYP3A4, such as verapamil, erythromycin, fluconazole, and
protease inhibitors. Conversely, the CYP3A4 inducer, St John’s
Wort, may reduce eplerenone levels by 30%.
Licensing restrictions
The licensing restrictions may have implications on which agent
can be prescribed in different geographical and ethnic groups.
Spironolactone is widely licensed for treatment of hypertension
and heart failure. In Europe and Canada, eplerenone is indicated for
patients with CHF and post-infarct LVSD, but not for the treatment
of essential hypertension.60 In the USA, eplerenone is indicated for
all these conditions, whilst in some Asian countries eplerenone is
indicated only for hypertension.22,61,62
Cost implications
Treatment with an MRA is cost-effective for the management of
CHF due to LVSD.63 In the absence of a randomized controlled
trial, it is difficult to establish the cost benefit of one agent
over the other. Although spironolactone is substantially cheaper,
eplerenone causes fewer side effects and may potentially be more
cost-effective in the management of post-infarct LVSD.64 The
incremental cost-effectiveness ratio of eplerenone, compared with
that of standard care alone (and not spironolactone), is £4457 and
£7893 for each additional quality-adjusted life year (QALY) when
2-year and lifetime treatment duration is assumed, respectively.64
These figures are well below the £20 000 threshold accepted as
good value by NICE, UK. The results of these health economic
analyses are based on higher relative effectiveness estimated
for eplerenone compared with spironolactone from the meta-
regression. However, if a ‘class effect’ is considered more plausible
than the results of an evidence synthesis model, spironolactone is
the most cost-effective treatment.
Cost-effectiveness analysis of the EMPHASIS-HF trial was
recently presented at the ESC Conference, showing that
eplerenone is cost-effective in CHF patients with mild symptoms, .
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.. by improving quality of life and reducing hospitalization (John
McMurray, ESC 2012). In addition to standard care, eplerenone
prescription increased lifetime direct costs by £3822 for the
UK, and €7239 for Spain, with additional quality-adjusted life
expectancy of 1.22 QALYs (UK, discount rate 3.5%) and 1.33 years
(Spain, discount rate 3%). Mean lifetime costs were £3140 per
QALY in the UK, €4312 per QALY in Greece, and €5442 per
QALY in Spain. Probabilistic sensitivity analysis suggested a 100%
likelihood of eplerenone being regarded as cost-effective at a will-
ingness to pay threshold of £20 000 per QALY (UK) or €30 000
per QALY (Spain). Therefore, by currently accepted standards of
value for money, the addition of eplerenone to optimal medical
therapy for patients with CHF and mild symptoms is likely to be
cost-effective.
Future directions
Head-to-head trial to evaluate side
effects
It would be difficult, if not impossible, to conduct a head-to-head
trial of these two drugs, due to the reasons already outlined.
However, as both drugs appear effective for many cardiovascular
indications and the main factor in decision-making relates to side
effect profile, it should be possible to conduct a small-scale trial
focusing on side effects, and not the efficacy, of these two drugs.
Personalized medicine
In the absence of direct comparative evidence, it should remain
perfectly acceptable (and preferable) to recommend one agent or
the other based on an individual patient’s profile, including gender,
co-morbidities, etc. This approach allows combining evidence-
based with personalzed medicine.
Non-steroidal mineralocorticoid
receptor antagonists
Both spironolactone and eplerenone are steroidal compounds.
There are a few non-steroidal MRAs at various stages of
development.65,66 It would be interesting to see if these compounds
Table 5 A suggested approach to select mineralocorticoid receptor antagonists for cardiovascular indications
Indication First-line MRA Selection of MRA
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Hypertension Spironolactone Consider gender (eplerenone for male patients)a and licensing restrictions
Chronic heart failure and LVSD Either Consider eplerenone for mild heart failure and male patients and spironolactone
for females or those with severe heart failure
LVSD post-MI Eplerenone
Diastolic heart failure Potentially spironolactone Consider eplerenone for male patients and switch to eplerenone for all patients
with side effects
PAH/RHF Neither Convincing pre-clinical data merit clinical trials
LVSD, left ventricular systolic dysfunction; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonist; PAH, pulmonary arterial hypertension; RHF, right heart
failure.
aThere are limited data supporting a gender-based approach in selecting MRAs and it could be argued to give eplerenone to male patients only if/when sexual side effects
occur.
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show similar efficacy, but have fewer side effects. Being non-
steroidal, it is envisaged that these compounds will have fewer
endocrine side effects. It is also being suggested that these com-
pounds may have higher affinity for cardiac MRs, rather than renal
MRs, and, therefore, potentially less tendency for hyperkalaemia.
BAY 94-8862 (Bayer Pharma, Germany) is currently being tested in
ARTS (minerAlocorticoid Receptor antagonist Tolerability Study;
NCT01345656) trial, and the results of this study will be of major
interest.66
Summary
There is a paucity of direct comparative data for spironolactone
and eplerenone. It may not be appropriate to compare trials using
spironolactone or eplerenone in heart failure directly due to vast
differences in patient population and trial design. Choice of a
specific agent could be based on clinical indications (such as the
nature of heart failure), individual patient factors (such as gender,
co-morbidities, occurrence of side effects), geographical licensing
restriction, and community-level cost–benefit analysis. Based on
the data available, we have suggested a simple approach to select a
particular MRA for various cardiovascular indications (Table 5). Fur-
ther comparative studies and cost–benefit analyses are warranted.
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